Japanese patent granted for Avecho’s TPM-enhanced CBD capsule
Avecho Biotechnology (ASX: AVE) has been granted a Japanese patent covering its proprietary TPM®-enhanced cannabidiol (CBD) capsule, adding to patents already secured in the United States and Europe. The grant, announced on 3 August 2026, extends protection across three of the world’s largest pharmaceutical markets.
Japan is the world’s third-largest pharmaceutical market, with insomnia affecting an estimated 14 million adults. The patent covers Avecho’s lead asset, which is currently undergoing pivotal Phase III clinical development for the treatment of insomnia.
When big ASX news breaks, our subscribers know first
Three of the world’s largest pharma markets now covered
The Japanese grant strengthens an international intellectual property portfolio that already spans two major jurisdictions. According to Avecho, the corresponding patents in the United States and Europe were granted prior to Japan, and each carries a long-dated protection window that de-risks the commercial pathway for the CBD capsule.
| Jurisdiction | Patent Status | Protection Runs To |
|---|---|---|
| United States | Granted | 2043 |
| Europe | Granted | 2041 |
| Japan | Granted (new) | 2041 |
| Other key territories | Applications in progress | TBD |
Key points from the update include:
-
Japan ranks as the world’s third-largest pharmaceutical market
-
Corresponding patent applications remain under review across all other key commercial territories
-
The IP portfolio is intended to support continued clinical development, commercialisation and regional licensing activities
Insomnia in Japan: a significant commercial opportunity
The commercial rationale behind the Japanese patent rests on the scale of the addressable market. Published studies estimate that insomnia affects around 13–14% of Japanese adults, equating to approximately 14 million people. Combined with Japan’s position as the third-largest pharmaceutical market globally, this represents a substantial opportunity for Avecho as it advances the CBD capsule towards registration.
CEO Commentary
“The grant of this patent in Japan represents another important step in establishing comprehensive global intellectual property protection for our CBD capsule. Japan joins the United States and Europe as jurisdictions where our core patent has now been granted, giving us protection across three of the world’s most significant pharmaceutical markets. With applications continuing to advance elsewhere, we are building a strong international patent position around our lead product as it moves through Phase III development,” said Dr Paul Gavin, Chief Executive Officer.
Understanding TPM® and why the CBD capsule matters
Avecho’s CBD capsule combines cannabidiol with the company’s proprietary Tocopheryl Phosphate Mixture (TPM®) drug delivery technology. TPM® is derived from Vitamin E using proprietary and patented processes, and has been demonstrated to improve the solubility and absorption of drugs and nutrients.
Avecho states that its TPM® technology has been demonstrated to improve the absorption of CBD.
The broader insomnia backdrop provides investor context:
-
Approximately 10–30% of the global population have symptoms of insomnia, with up to 237 million people affected worldwide
-
The sleep economy and sleep aids market is estimated to reach US$950 billion by 2032
-
In Australia, as many as 60% of the population have at least some symptoms of insomnia, with a total economic cost estimated at A$19.1 billion
-
The Australian over-the-counter CBD market was initially projected to grow to over US$125 million per annum
The Phase III catalyst and what comes next
The value of the newly granted patents is tied closely to Avecho’s near-term clinical catalyst. The company is conducting a pivotal Phase III trial described as multi-centre, randomised, double-blind and placebo-controlled, and reported to be the largest of its kind testing cannabidiol. The trial takes place at multiple sites across Australia.
The Phase III trial cleared to continue at its original 519-participant sample size following an independent Data Monitoring Board review, with zero serious adverse events recorded across the 244 participants assessed at interim, reinforcing the tolerability profile central to Avecho’s commercial positioning.
Participants are randomly assigned to receive nightly doses of either 75mg or 150mg of CBD, or a placebo, over an eight-week period. The trial has been designed to meet the requirements of the Therapeutic Goods Administration (TGA), the US Food and Drug Agency and the European Medicines Agency.
A successful Phase III trial would represent Avecho’s final clinical step in support of a submission to the TGA for pharmaceutical registration. Regulatory changes introduced in Australia in 2020 allow over-the-counter sales of CBD products direct from pharmacy without a prescription, provided appropriate approvals are obtained. Avecho notes it has an opportunity to be a first-mover in this area, as no other Phase III CBD trials in Australia have succeeded.
Granted patents across the three largest pharmaceutical markets are positioned to protect the commercial and licensing value of the CBD capsule should the trial succeed.
For investors wanting to understand the clinical and commercial implications in full, our deep-dive into the interim analysis outcome covers what the Data Monitoring Board’s recommendation means for the TGA registration pathway, the Sandoz partnership economics, and the indicative licensing multipliers management has cited for the US market.
Investment takeaway
Avecho is building a defensible, long-dated global IP position around a Phase III asset targeting a large and underserved insomnia market. Protection now runs to 2043 in the United States and to 2041 in both Europe and Japan, while further patent applications continue to advance across other key commercial territories. The outcome of the ongoing Phase III trial remains the primary value inflection to watch.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000+ subscribers trust it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to get the next big update the moment it lands.